


Amendment to the Claims:

The listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims

- 1-8. (Cancelled)
9. (Currently amended) A method for treating a tumor, said method comprising the steps of: (a) providing a composition comprising an effective amount of a compound of formula



wherein R₁, R₂, R₃, and R₄ independently represent -OH, -OCH₃, -O(C=O)CH₃, or ~~an a~~ substituted or unsubstituted amino acid residue or substituent or salt thereof, but are not each -OH simultaneously; and (b) applying the composition to the tumor, ~~wherein the effective amount is any amount greater than 0 μM.~~

10. (Previously presented) The method of claim 9, wherein said tumor is present in a mammal.
11. (Previously presented) The method of claim 10, wherein said tumor is malignant.
12. (Previously presented) The method of claim 10, wherein said tumor is benign.
13. (Previously presented) The method of claim 10, wherein said tumor is selected from the group consisting of papilloma, teratoma and adenoma.

14. (Previously presented) The method of claim 10, wherein said tumor is a solid tumor.
15. (Previously presented) The method of claim 10, wherein said mammal is a human.
16. (Previously presented) The method of claim 10, wherein said tumor is derived from transformed cells.
17. (Cancelled)
18. (Previously presented) The method of claim 9, wherein said compound is administered along with at least one pharmaceutically excipient or carrier.
19. (Previously presented) The method of claim 18, wherein said excipient or carrier is dimethylsulfoxide.
20. (Currently amended) The method of claim 9, wherein said compound is tetra-O-methyl nordihydroguaiaretic acid or ~~tetraglycyl nordihydroguaiaretic acid~~ meso-1,4-bis[3,4-(dimethylaminoacetoxy)phenyl]-(2R,3S)-dimethylbutane.
21. (Cancelled)
22. (Previously presented) A method of suppressing Sp1 regulated promoter activity in a cell comprising the steps of: (a) providing a composition comprising tetra-O-methyl nordihydroguaiaretic acid (M₄N); and (b) exposing the cell to a concentration of M₄N, wherein concentration of M₄N is a number greater than 0 μM.
23. (Previously presented) The method of claim 22, wherein the M₄N concentration is selected from the group consisting of: at least about 10 μM, at least about 20 μM, at least about 30 μM, at least about 40 μM, at least about 50 μM and at least about 60 μM.

24. (Previously presented) A method of suppressing Sp1 regulated promoter activity in a cell comprising the steps of: (a) providing a composition comprising tetra-glycynyl NDGA (G_4N); and (b) exposing the cell to a concentration of G_4N , wherein concentration of G_4N is a number greater than 0 μM .

25. (Previously presented) The method of claim 24, wherein the G_4N concentration is selected from the group consisting of: at least 20 μM , at least 40 μM , at least 60 μM , at least 80 μM and at least 100 μM .

26. (Previously presented) The method of claim 24, wherein the G_4N concentration is selected from the group consisting of: at least about 0.25 mM, at least about 0.5 mM, at least about 0.75 mM, at least about 1.0 mM, at least about 1.25 mM, at least about 1.5 mM, and at least about 1.75 mM.

27. (Previously presented) A method of suppressing tumor cell growth comprising the steps of: (a) providing a composition comprising tetra-O-methyl nordihydroguaiaretic acid (M_4N); and (b) exposing the tumor cell to a concentration of M_4N , wherein concentration of M_4N is a number greater than 0 μM .

28. (Previously presented) The method of claim 27, wherein the concentration of M_4N is selected from the group consisting of at least about 10 μM , at least about 20 μM , at least about 30 μM , at least about 40 μM , at least about 50 μM , at least about 60 μM , at least about 70 μM , at least about 80 μM , at least about 90 μM , and at least about 100 μM .

29. (Previously presented) The method of claim 27, wherein the step of exposing the tumor cell to a concentration of M_4N comprises exposing the tumor cell for a number of hours greater than 0.

30. (Previously presented) The method of claim 29, wherein the number of hours is selected from the group consisting of at least about 24 hr, at least about 48 hr, and at least

about 70 hr.

31. (Previously presented) The method of claim 29, wherein the number of hours is at least 72.

32. (Previously presented) The method of claim 9, wherein the concentration of the compound is selected from the group consisting of: at least 20 μM , at least 40 μM , at least 60 μM , at least 80 μM and at least 100 μM .

33. (Currently amended) The method of claim 9, wherein the concentration of the compound is selected from the group consisting of at least about 10 μM , at least about 20 μM , at least about 30 μM , at least about 40 μM , at least about 50 μM , at least about 60 μM , at least about 70 μM , at least about 80 μM , at least about 90 μM , and at least about 100 μM .